Cambridge startup analyses ‘multi-omics’ data to discover new heart drugs

Cambridge-based CardiaTec has raised $6.5mn to accelerate drug discovery for cardiovascular diseases, such as heart attacks and strokes. Cardiovascular diseases are the leading cause of death globally, claiming the lives of 17.9 million people each year. Yet our knowledge of their underlying biology is still limited, hindering the effectiveness of clinical trials and drug solutions. CardiaTec aims to address this knowledge gap with a drug discovery platform that leverages AI to analyse human tissue “multi-omics” data. Mutli-omics is a biological analysis approach which combines the study of multiple “omes,” the sets of various biological molecules or entities within a cell…

This story continues at The Next Web

from LatestTechyTalks